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effects. Meta-analysis of head-to-head comparisons represents a
robust method for anticipating the beneﬁt and risk of an emer-
gent statin, such as rosuvastatin, in comparison to an extensively
studied agent such as atorvastatin. METHODS: A systematic
literature search to identify head to head clinical studies of R and
A was conducted. Data were available for 30 comparisons of 1:1
dose ratios (R10mg vs. A10mg etc), 24 comparisons of 1:2 dose
ratios (R5mg vs. A10mg etc) and six comparisons of 1:4 dose
ratios (R5mg vs. A20mg etc). Treatment difference in beneﬁt (%
Low Density Lipoprotein-cholesterol [LDL-c] reduction) and
risk (odds ratios for myalgia, serious adverse events and with-
drawals due to adverse events, elevated Alaninaminotransferase
[ALT] (3xULN), and Creatine Kinase [CK] (>10xULN), were
estimated by meta-analysis (random effects) and presented in
beneﬁt risk planes. RESULTS: Analysis of 25 studies
(~24,000 pts) demonstrated rosuvastatin to be signiﬁcantly more
efﬁcacious than atorvastatin, for LDL-c reduction, at 1:1 and 1:2
dosage ratios. There were no signiﬁcant differences between
rosuvastatin and atorvastatin, at any dose ratio, for i) withdraw-
als due to adverse events, ii) myalgia, iii) serious adverse events,
iv) death, v) ALT > 3x upper limit of normal (ULN), and vi)
creatine kinase (CK) >10xULN. CONCLUSION: At 1:1 and 1:2
dose ratios, signiﬁcant additional reductions in LDL-c are
obtained by rosuvastatin at a comparable risk of the adverse
events presented.
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OBJECTIVE: To extend beyond the current approach of predict-
ing warfarin beneﬁt and harm independently in new atrial ﬁbril-
lation (AF) patients by reﬁning methods to identify predictors
of the four combined beneﬁt/harm outcome groups—i) no
stroke/no bleed; ii) no stroke/bleed; iii) stroke/bleed; iv) no
stroke/no bleed. METHODS: We analyzed patient-level data
from the Atrial Fibrillation Investigators RCT database
(n = 9155) and an observational database of AF patients
managed by Kaiser Permanente Colorado (n = 5475). We classi-
ﬁed patients based on the four beneﬁt/harm outcome groups and
applied decision tree modeling (CART) and polytomous logistic
regression (PLR) to identify patient factors predicting each
outcome group. Statistical signiﬁcance was set at alpha = 0.05.
RESULTS: CART and PLR consistently identiﬁed age and war-
farin use as predictors for all outcome groups. Both techniques
identiﬁed predictors of stroke/no bleed and no stroke/bleed not
previously included in AF stroke and bleed risk-assessment tools
that predict these outcomes independently (e.g., CHADS2 and
HEMORR2HAGES). Methodology strengths and limitations
were evident. CART provides a visual algorithm approach to
risk. However, there is a lack of quantitative measurement (e.g.,
odds ratios [OR], conﬁdence intervals) for predictors. While PLR
results were thorough and predictor parameter estimates could
be converted to ORs to indicate strength of association, the result
of PLR is number-intensive. To calculate a patient’s probability
for each of the four outcome groups, the patient’s data must be
inputted into three separate equations. While both techniques
can be used to calculate an individual patient’s probability for
each outcome group, PLR likely has more scope for application
in a clinical setting. Once reﬁned, a clinical prediction rule could
be created based on identiﬁed predictors and their ORs.
CONCLUSION: While methods under study need further reﬁne-
ment, these individual patient data analyses provide a useful step
forward in the movement towards evidence-based individualiza-
tion of drug therapy.
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OBJECTIVE: Angina is relieved by CABG, PCI and stenting
procedures but reoccurs over time in a percentage of patients.
Little is known about the frequency of recurrent angina follow-
ing percutaneous and surgical procedures, the characteristics
which put a patient at risk for recurrent angina and the timing
of angina recurrence. METHODS: Patients enrolled in a large
national managed care plan with a claim for a CABG, PCI or
stent from January 1, 2003 to Decemeber 31, 2004 were selected
if they were 35 or older, and enrolled one year prior and one year
following their procedure. Patients were followed for one year
after their index procedure for medication use, angina diagnosis
by ICD-9 code and additional revascularization procedures.
RESULTS: Following selection criteria 18,240 patients were eli-
gible for analysis. The average age was 59 years, with 25% age
65 years and older. Most patients were male (78%). Of the
18,240 patients, 46% (8420) experienced angina (identiﬁed
by angina diagnosis and/or two or more nitrate prescriptions)
within a year following their index procedure. Of those patients
experiencing angina, approximately a third (30%/2904) had
another revascularization procedure following the angina diag-
nosis. The average time from initial procedure to second proce-
dure, after angina diagnosis, was 73 days, although there is a
wide range among patients (SD = 103 days). Risk factors for
having angina following a revascularization procedure were
younger age, female gender and having a PCI without a stent.
CONCLUSION: Angina reoccurs in a considerable percentage of
patients in the year following a percutaneous or surgical coro-
nary procedure. A third of patients experiencing angina have a
second procedure after experiencing recurrent angina.
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OBJECTIVE: Resistant hypertension is deﬁned as the failure to
reach blood pressure (BP) goals while treated at adequate doses
with three or more antihypertensive agents (AHYs) where one is
a diuretic. Clinical trials have found that 2–15% of treated
patients have resistant hypertension. The exact prevalence of
resistant hypertension in clinical practice is unknown. This
analysis evaluates the prevalence of resistant hypertension in a
real-world setting. METHODS: Hypertensive patients aged 18
and older were identiﬁed from the General Electric Electronic
Medical Records (EMR) database during the period of Novem-
ber 1, 2002 to November 30, 2005. Resistant hypertension was
deﬁned as a blood pressure reading over 140/90 mmHg (130/
80 mmHg for patients with diabetes or kidney disease) within
one year after the last AHY agent was prescribed during a
treatment observation window of November 1, 2003 to Novem-
ber, 2004. RESULTS: A total of 29,474 hypertensive patients
were identiﬁed with an average age of 63.3 years (SD  13.3)
Abstracts A189
